Para que serve o gel de sirolimo?

O gel de sirolimo 0,2% Ã© um inibidor de mTOR de uso tÃ³pico indicado para o angiofibroma facial associado ao complexo da esclerose tuberosa em adultos e crianÃ§as a partir de 6 anos, conforme a bula aprovada. Ã um medicamento sob prescriÃ§Ã£o, utilizado com acompanhamento mÃ©dico, geralmente de um dermatologista. A PharmaTradz ajuda importadores autorizados, distribuidores e hospitais a adquirir gel de sirolimo de fabricantes com certificaÃ§Ã£o GMP.

Ã quoi sert le gel de sirolimus ?

Le gel de sirolimus Ã 0,2 % est un inhibiteur de mTOR Ã usage cutanÃ© indiquÃ© dans l'angiofibrome facial associÃ© Ã la sclÃ©rose tubÃ©reuse de Bourneville, chez l'adulte et l'enfant Ã partir de 6 ans, selon le rÃ©sumÃ© des caractÃ©ristiques du produit. C'est un mÃ©dicament sur ordonnance, utilisÃ© sous surveillance mÃ©dicale, gÃ©nÃ©ralement celle d'un dermatologue. PharmaTradz aide les importateurs agrÃ©Ã©s, les distributeurs et les hÃ´pitaux Ã s'approvisionner en gel de sirolimus auprÃ¨s de fabricants certifiÃ©s GMP.

Sirolimus Gel bulk supplier for pharma manufacturers

Sirolimus Gel 0.2% gel Suppliers & Bulk Manufacturers

Q: Â¿Para quÃ© sirve el gel de sirÃ³limus?

El gel de sirÃ³limus al 0,2 % es un inhibidor de mTOR de uso tÃ³pico indicado para el angiofibroma facial asociado al complejo de esclerosis tuberosa en adultos y niÃ±os a partir de 6 aÃ±os, segÃºn la ficha tÃ©cnica aprobada. Es un medicamento con receta que se utiliza bajo la supervisiÃ³n de un mÃ©dico, normalmente un dermatÃ³logo. PharmaTradz ayuda a importadores con licencia, distribuidores y hospitales a abastecerse de gel de sirÃ³limus de fabricantes con certificaciÃ³n GMP.

Available Forms: Gel

Available Strengths: 0.2% gel

Reference Brands: HYFTOR (USA)

Category: Derma Drugs

Sirolimus topical gel is a mTOR (mechanistic target of rapamycin) inhibitor formulated for cutaneous application. It is indicated for the treatment of facial angiofibromas associated with tuberous sclerosis complex (TSC) in patients aged 2 years and older. The gel works by inhibiting abnormal cell growth and proliferation, helping to reduce the size, redness, and thickness of skin lesions.

Ask About Access

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Sirolimus Gel? List it or send an offer →

Product Description:

Sirolimus inhibits mTOR, a kinase that integrates growth signals and drives cell proliferation. In tuberous sclerosis complex the TSC1 or TSC2 gene is defective, the brake on mTOR is missing, and the pathway runs unchecked — producing benign tumours in multiple organs, including the facial angiofibromas that appear across the nose and cheeks in childhood. Applying the inhibitor directly to the skin blocks that pathway where the lesions are, without the systemic immunosuppression that oral sirolimus causes.

The 0.2% gel is used for facial angiofibromas associated with tuberous sclerosis complex in patients aged two and over, applied thinly once daily. Lesions become less red, less raised and smaller over months of continued use, and they recur if treatment stops. This matters more than a cosmetic framing suggests: the lesions are disfiguring, highly visible, and appear during childhood. Application site irritation, dryness and stinging are the common effects; systemic absorption is low but measurable.

Sourcing notes. Originator product, on patent, with approval in a limited number of territories — confirm before quoting. A rare-disease dermatology product with small volumes through specialist clinics. Note this is a topical product and is in no way interchangeable with oral sirolimus. Store as labelled; confirm refrigeration requirements per presentation.

Also known as: sirólimus (Spanish), sirolimo (Portuguese), sirolimus (French, Italian, Turkish, Vietnamese), Sirolimus (German), сиролимус (Russian), سيروليموس (Arabic), 西罗莫司 (Chinese), シロリムス (Japanese), 시롤리무스 (Korean).

How Sirolimus Gel is supplied today, and licensing ahead of patent expiry

Sirolimus Gel is a patented innovator medicine. Where its patents are in force, which today includes most major markets, it can only be supplied by the originator or its licensees, through the routes below. Patents do expire, though, and generic development and licensing deals for post-patent markets start years in advance. If you are developing Sirolimus Gel, hold a dossier for it or want to license it, talk to us.

Named-patient import Where a patient needs the product in a market where it is not registered, named-patient import is the lawful route. It requires the treating physician's documentation and authorisation from the destination regulator. We handle this pathway. Named-patient access

Authorised distribution For registered markets, supply runs through the manufacturer's authorised distribution channel. We can identify the authorised route for your market and tell you whether the product is registered there at all. Innovator sourcing

A genericised alternative Where the clinical requirement is the drug class rather than this specific molecule, there is often an off-patent alternative that is faster to register and materially cheaper. Tell us the indication and target market and we will say plainly whether one exists. Discuss alternatives

Licensing and generic development Patents expire country by country, and in many countries development and dossier filing can start before expiry under research and regulatory-review exemptions. We connect manufacturers developing this molecule, dossier holders, licensees and tech-transfer partners for markets where it is, or will become, off-patent. Partner on this molecule

Ask about Sirolimus Gel supply →

Back to Listing

Frequently Asked Questions

Hyftor (Sirolimus 0.2% Gel) is developed and sold by Nobelpharma (Rapalimus gel in Japan). PharmaTradz handles enquiries for authorised supply of the originator product, named-patient import where it is not registered, and licensing or development work ahead of patent expiry.

El gel de sirólimus al 0,2 % es un inhibidor de mTOR de uso tópico indicado para el angiofibroma facial asociado al complejo de esclerosis tuberosa en adultos y niños a partir de 6 años, según la ficha técnica aprobada. Es un medicamento con receta que se utiliza bajo la supervisión de un médico, normalmente un dermatólogo. PharmaTradz ayuda a importadores con licencia, distribuidores y hospitales a abastecerse de gel de sirólimus de fabricantes con certificación GMP.

O gel de sirolimo 0,2% é um inibidor de mTOR de uso tópico indicado para o angiofibroma facial associado ao complexo da esclerose tuberosa em adultos e crianças a partir de 6 anos, conforme a bula aprovada. É um medicamento sob prescrição, utilizado com acompanhamento médico, geralmente de um dermatologista. A PharmaTradz ajuda importadores autorizados, distribuidores e hospitais a adquirir gel de sirolimo de fabricantes com certificação GMP.

Le gel de sirolimus à 0,2 % est un inhibiteur de mTOR à usage cutané indiqué dans l'angiofibrome facial associé à la sclérose tubéreuse de Bourneville, chez l'adulte et l'enfant à partir de 6 ans, selon le résumé des caractéristiques du produit. C'est un médicament sur ordonnance, utilisé sous surveillance médicale, généralement celle d'un dermatologue. PharmaTradz aide les importateurs agréés, les distributeurs et les hôpitaux à s'approvisionner en gel de sirolimus auprès de fabricants certifiés GMP.